Preclinical Contract Research Services
By disease area
CNS
Visualize and quantify your drug’s effects on the brain to progress your study with more certainty.
Non-rodent Studies
Use Gubra’s state-of-the-art PK, NGS and bioinformatics platform in miniature pigs.
By technology
Imaging services across indications
Visualize and quantify
your drug’s effects
Gubra offers state-of-the art 3D imaging technologies to visualize pathogenesis and drug distribution in brain and organs at single cell resolutions.
Gubra CRO
17/20
of the largest global pharmaceutical companies choose Gubra for their preclinical studies
Meet the team
Our team blends scientific insight and excellence with commercial acumen to create collaborations built on trust and long-term value.
Trine Nygaard Hamann
Head Gubra CRO
Read bio
Trine Nygaard Hamann, Head of Gubra CRO Trine leads Gubra’s global preclinical contract research organization. She has held senior leadership roles at Gubra since 2017, including Chief Business Officer, where she oversaw commercial strategy, sales and marketing and led the opening of Gubra’s first U.S. office in Boston. Trine holds an Executive MBA from AVT Business School, Denmark.
Michael Christensen
Head of Scientific Sales
Read bio
Michael Christensen, Ph.D., Head of Sales Michael leads sales at Gubra, where he has worked since 2019. He combines a scientific background within vivo pharmacology with experience in key account management and business development.
Michael holds a Ph.D. from Aarhus University, Denmark where his research focused on renal disease, and has conducted research stays at universities in Sweden and the USA.
Alexis Santana
Head of CRO Business Development, US
Read bio
Alexis Santana, Ph.D., Head of CRO Business Development, US Alexis leads Gubra’s CRO business development in the US, having joined in 2026. Alexis brings 8 years of experience in life sciences business development with a focus on preclinical and translational research services and models. She previously held director-level roles at Samsung Biologics, Tempus AI and The Jackson Laboratory. Alexis holds a Ph.D. in Molecular Genetics and Microbiology from Stony Brook University and an Executive MBA from Rutgers Business School.
We measure our success by the value we create for our customers. Our role is to turn complex research questions into clear insights that help select promising drug candidates and move development forward quickly”
Trine Nygaard Hamann
Head Gubra CRO
EVENTS CALENDAR for CRO
Meet us here
Obesity & Weight Loss Drug Development Summit Europe
Gubra will attend Obesity & Weight Loss Drug Development Summit Europe on October 28–29, 2026 in Munich, Germany.
The Obesity & Weight Loss Drug Development Summit Europe is organized by Hanson Wade. It focuses on the next generation of weight-loss therapeutics beyond first-generation GLP-1s, including new targets, combination therapies, tolerability, muscle preservation and more convenient dosing. It is aimed at drug developers, most of them director level or above.
AASLD – The Liver Meeting
Gubra will attend AASLD – The Liver Meeting on November 5–9, 2026 in Denver, CO.
The Liver Meeting is the annual meeting of the American Association for the Study of Liver Diseases (AASLD). It presents research and clinical advances in hepatology and opens with a postgraduate course. More than 2,900 abstracts have been released for the 2026 meeting at the Colorado Convention Center.
Gubra Investor R&D Event 2026
A deep dive into Gubra’s differentiated innovation model, pipeline, and 2030 strategy.
October 27, 2026 · 1.00–5.00 pm GMT · London (2 Stonecutter Street) or via Webcast.
For further information